Published analyses of peripheral analytes in advanced renal cell carcinoma (aRCC) are limited. In this study, Choueiri, Donahue, and colleagues present findings from integrated analyses of longitudinal blood samples and baseline tumor tissue from the JAVELIN Renal 101 trial (N = 886), which represents one of the largest data sets for aRCC to date. The findings demonstrate different immunomodulatory mechanisms associated with efficacy outcomes in patients treated with avelumab plus axitinib versus sunitinib and in subsets of patients with different tumor microenvironments and genotypes. Novel treatment-specific observations may prove to have prognostic or predictive significance in the treatment of aRCC.

See article, p. 406.

Neuroendocrine prostate cancer is an aggressive variant of advanced prostate cancer that is currently diagnosed by tumor biopsy. In this study, Franceschini and colleagues developed the NEuroendocrine MOnitoring (NEMO) targeted cell-free DNA (cfDNA) methylation assay, which provides a phenotype evidence score that captures diverse...

You do not currently have access to this content.